Vaccibody AS - Private Placement - NOK 230 million
The net proceeds will i.a. be used to conduct a Phase IIa clinical study combining Vaccibody’s product candidate VB10.16 with Roche’s checkpoint inhibitor Atezolizumab, prepare for expansion cohorts in Vaccibody’s VB10.NEO cancer neoantigen programme and initiation of two expansion cohorts.
Latest news
Arctic Securities - Arctic top-ranked in Prospera 2025
Arctic Securities secured several leading positions in the Prospera Nordic High Yield Investor Survey 2025.
Arctic Securities - Arctic Securities Partners with Børsgruppen Aktie
Arctic Securities is pleased to partner with Børsgruppen Aktie at BI Norwegian Business School.
Arctic Securities - Welcome to Arctic, Jonas Abrahamsen!
Arctic is proud to welcome professional cyclist Jonas Abrahamsen as our newest ambassador.
Arctic Securities - Leadership Changes – Strengthening Arctic for the Future
We are pleased to announce leadership transitions at Arctic to support our long-term vision and continued success.
Arctic Securities - Arctic Securities er sertifisert rådgiver på Nasdaq First North Growth Market
Arctic Securities er godkjent som Certified Adviser (CA) på den alternative markedsplassen Nasdaq First North Growth Market i Sverige.
Arctic Securities - Arctic bøtelagt i Sverige – uenig i regelbrudd
Disiplinærnemnden ved Nasdaq Stockholm gir Arctic Securities en bot på 2 millioner SEK for ikke å ha informert børsen tidsnok om en endring i virksomheten.